Manufacturers Say 340B Penalties Proposal Could Punish Actions Outside Their Control
This article was originally published in The Pink Sheet Daily
Executive Summary
HRSA's proposed rule on civil monetary penalties conflicts with statute's requirement that penalties be imposed only for knowing and intentional program violations, trade groups say.
You may also be interested in...
340B Manufacturer Fines Outlined In Rule, But HRSA Expects To Use Them ‘Very Rarely’
Proposed rule would implement how civil monetary penalties will be applied to manufacturers that “knowingly and intentionally” deny 340B prices to eligible health care providers.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.